Investigation of response of patients with non ‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment

ConclusionsOur results suggest that DTX and DTX  + RAM therapies immediately after treatment with ICI-containing regimens as well as continuation of DTX without dose reduction after the second cycle may increase the response rate and prolong survival in patients with NSCLC.

Source: Thoracic Cancer - November 15, 2023 Category: Cancer & Oncology Authors: Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa Tags: ORIGINAL ARTICLE Source Type: research